Key Highlights

  • Scinai Immunotherapeutics shares closed up 47% at $2.44.
  • The company terminated its PC111 option and license agreement with PinCell following a denied extension request.
  • Scinai is redirecting R&D efforts toward its NanoAb pipeline and IL-17 candidates.
  • The company's CDMO operations held roughly $3.1 million in contracted customer orders as of August 16, with projected 2026 CDMO sales of about $5 million.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) shares closed up 47% at $2.44 after the company terminated its PC111 option and license agreement with PinCell following a denied extension request.

What Happened

The move redirects R&D efforts toward Scinai's NanoAb pipeline and IL-17 candidates to conserve Capital for its expanding CDMO operations, which held roughly $3.1 million in contracted customer orders as of August 16 while projecting around $5 million in 2026 CDMO sales.

Market Reaction

Shares surged sharply as investors responded to the capital conservation move and the sharper strategic focus on the NanoAb pipeline, IL-17 candidates, and the growing CDMO business.

Outlook

Continued growth of Scinai's CDMO operations, alongside progress on its NanoAb pipeline and IL-17 candidates, represents the next relevant developments for the company following the PC111 termination.